Overview

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with or without bone marrow transplantation in treating patients who have acute lymphocytic leukemia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Southwest Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
6-Mercaptopurine
Asparaginase
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Doxorubicin
Etoposide
Leucovorin
Levoleucovorin
Liposomal doxorubicin
Mercaptopurine
Methotrexate
Prednisone
Thioguanine
Vincristine
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed acute lymphocytic leukemia FAB class
L1-L2 Mixed immunophenotypic markers with no cytochemical myeloid markers allowed No
non-Hodgkin's lymphoma No chronic myelogenous leukemia in blast crisis Concurrent
registration on the cytogenetics protocol SWOG-9007 required

PATIENT CHARACTERISTICS: Age: 15 to 65 Performance status: SWOG 0-3 Hematopoietic: Not
specified Hepatic: Bilirubin no greater than 2 times normal (unless elevation due to
leukemia) AST no greater than 3 times normal (unless elevation due to leukemia) No chronic
liver disease Renal: Creatinine no greater than 2 times normal Cardiovascular: Left
ventricular ejection fraction at least 50% by MUGA or echocardiogram No symptomatic
congestive heart failure No symptomatic coronary artery disease No cardiomyopathy No
uncontrolled arrhythmia Other: Not pregnant or nursing Fertile patients must use effective
contraception

PRIOR CONCURRENT THERAPY: No prior remission induction chemotherapy for acute lymphocytic
leukemia